BACKGROUND: Patients with mild cognitive impairment (MCI) may be especially vulnerable to the side effects of potentially inappropriate medications (PIMs), especially those that impair cognition. METHODS: We conducted a cross-sectional study to determine the prevalence of PIM use among 689 patients with MCI. We used the 2003 Beers Criteria for cognitive impairment to identify PIMs. We then determined if certain patients were more likely to use PIMs. RESULTS: There were 143 (20.8%) patients with MCI taking a PIM: 108 (15.7%) patients were taking one PIM and 35 (5.1%) patients were taking two or more PIMs. The most common PIMs were anticholinergics (35.7%) and benzodiazepines (31.5%). Patients were more likely to be taking PIMs if they were women and were taking a greater number of medications and less likely if they had a history of myocardial infarction. CONCLUSIONS: Patients with MCI are frequently taking PIMs that may negatively affect cognition. Future research is needed to assess whether cognitive impairment symptoms are improved if PIM use is reduced.
BACKGROUND:Patients with mild cognitive impairment (MCI) may be especially vulnerable to the side effects of potentially inappropriate medications (PIMs), especially those that impair cognition. METHODS: We conducted a cross-sectional study to determine the prevalence of PIM use among 689 patients with MCI. We used the 2003 Beers Criteria for cognitive impairment to identify PIMs. We then determined if certain patients were more likely to use PIMs. RESULTS: There were 143 (20.8%) patients with MCI taking a PIM: 108 (15.7%) patients were taking one PIM and 35 (5.1%) patients were taking two or more PIMs. The most common PIMs were anticholinergics (35.7%) and benzodiazepines (31.5%). Patients were more likely to be taking PIMs if they were women and were taking a greater number of medications and less likely if they had a history of myocardial infarction. CONCLUSIONS:Patients with MCI are frequently taking PIMs that may negatively affect cognition. Future research is needed to assess whether cognitive impairment symptoms are improved if PIM use is reduced.
Authors: J Ellul; N Archer; C M L Foy; M Poppe; H Boothby; H Nicholas; R G Brown; S Lovestone Journal: J Neurol Neurosurg Psychiatry Date: 2006-09-29 Impact factor: 10.154
Authors: Denys T Lau; Nathaniel D Mercaldo; Joseph W Shega; Alfred Rademaker; Sandra Weintraub Journal: Am J Alzheimers Dis Other Demen Date: 2011-12-28 Impact factor: 2.035
Authors: David P O'Sullivan; Denis O'Mahony; Carole Parsons; Carmel Hughes; Kevin Murphy; Susan Patterson; Stephen Byrne Journal: Drugs Aging Date: 2013-01 Impact factor: 3.923
Authors: Amanda J Cross; Johnson George; Michael C Woodward; David Ames; Henry Brodaty; Jenni Ilomäki; Rohan A Elliott Journal: Drugs Aging Date: 2016-01 Impact factor: 3.923